VERTEX PHARMACEUTICALS INC / MA Finance Lease, Right-of-Use Asset, after Accumulated Amortization
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $81.50 million as of 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-02-13
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $81.50M.
- 2024-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $57.90M.
- 2024-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $90.30M.
- 2023-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $272.80M.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization | Finance Lease, Right-of-Use Asset, after Accumulated Amortization as first filed |
|---|---|---|
| 2025-12-31 | $81.50M 10-K · filed 2026-02-13 | |
| 2024-12-31 | $57.90M 10-K · filed 2026-02-13 | |
| 2024-09-30 | $90.30M 10-Q · filed 2024-11-05 | |
| 2023-12-31 | $272.80M 10-K · filed 2025-02-13 | |
| 2022-12-31 | $315.50M 10-K · filed 2024-02-15 | |
| 2021-12-31 | $400.10M 10-K · filed 2023-02-10 | |
| 2020-12-31 | $431.20M 10-K · filed 2022-02-09 | $431.19M 10-K · filed 2021-02-11 |
| 2019-12-31 | $445.34M 10-K · filed 2021-02-11 | |
| 2019-09-30 | $449.35M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $461.55M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $473.13M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $640.95M 10-Q · filed 2019-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |